Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
Infectious agent detection by nucleic acid (DNA or RNA) for Trichomonas vaginalis is a diagnostic procedure aimed at identifying the presence of this specific protozoan parasite, which is responsible for the sexually transmitted infection known as trichomoniasis. Trichomonas vaginalis (T. vaginalis) is a single-celled organism that can lead to various symptoms, including vaginal itching, burning sensations, abnormal discharge, discomfort during sexual intercourse, and painful urination. The procedure utilizes a direct probe technique, which is a form of nucleic acid testing that allows for the rapid detection of the pathogen. This method can often be performed in a physician's office using a specialized test kit. The process begins with the collection of a vaginal swab, which is then treated with a lysate to break down cellular structures and release nucleic acids. Following this, the lysate is introduced into a sample well where a T. vaginalis-specific probe is attached to a stationary microparticle bead. This bead captures the target DNA sequence, facilitating the identification of the organism. Subsequent washing steps remove any unbound materials, and the addition of a second probe with a color development substrate allows for visual confirmation of the test results. A color change indicates the presence of T. vaginalis, while the absence of color signifies a negative result.
© Copyright 2026 Coding Ahead. All rights reserved.
Infectious agent detection by nucleic acid (DNA or RNA) for Trichomonas vaginalis is indicated for the following conditions:
The procedure for detecting Trichomonas vaginalis using nucleic acid testing involves several key steps:
After the procedure, the results of the nucleic acid test for Trichomonas vaginalis are typically available within a short timeframe, allowing for prompt diagnosis and treatment if necessary. Patients may be advised to follow up with their healthcare provider to discuss the results and any potential treatment options. It is also important for patients to be informed about the need for partner notification and treatment to prevent reinfection and further transmission of the disease. Additionally, healthcare providers may recommend routine screening for sexually transmitted infections for individuals at higher risk to ensure ongoing sexual health.
| Short Descr | TRICHOMONAS VAGIN DIR PROBE | Medium Descr | IADNA TRICHOMONAS VAGINALIS DIRECT PROBE TQ | Long Descr | Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, direct probe technique | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 206 - Microscopic examination (bacterial smear, culture, toxicology) |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | Q4 | Service for ordering/referring physician qualifies as a service exemption | GA | Waiver of liability statement issued as required by payer policy, individual case | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 26 | Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number. | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | CR | Catastrophe/disaster related | GV | Attending physician not employed or paid under arrangement by the patient's hospice provider | GW | Service not related to the hospice patient's terminal condition | GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit | GZ | Item or service expected to be denied as not reasonable and necessary | KX | Requirements specified in the medical policy have been met | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2011-01-01 | Changed | Short description changed. |
| 2004-01-01 | Added | First appearance in code book in 2004. |
Get instant expert-level medical coding assistance.